Industries de la santé
24 Octobre 2016
London – 24 October 2016 - The US market for major depressive disorders (MDD) will rise from $2.4 billion in 2015 to $4.6 billion by 2025, at a strong compound annual growth rate (CAGR) of 6.6%, according to research and consulting firm GlobalData. |The company’s report states that the US will not only remain the largest major market for MDD drugs, but will extend its lead over other...
Plus d'articles...
- Juntendo University research: Brain microcircuit for higher cognitive functions is identified
- Biocorp lance Inspair, le capteur intelligent qui transforme les inhalateurs en dispositifs connectés pour les patients asthmatiques ou atteints de Broncho Pneumopathie Chronique Obstructive (BPCO)
- Okayama University research: Photoreactive compound allows protein synthesis control with light
- OSE Immunotherapeutics présente des résultats précliniques d'Effi-DEM, checkpoint inhibiteur de nouvelle génération sur l'axe stratégique SIRP-α/CD47, à la Conférence « Immune Checkpoint Inhibitors» 16 - 18 novembre 2016, Munich